Sign In
Buy UTHR
$549.47
+9.42 (+1.74%)
At Close: Jun 03, 2026
United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
04:03pm, Tuesday, 23'rd Sep 2025
United Therapeutics Corporation (NASDAQ:UTHR ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT Company Participants Harrison Silvers Martine Rothblatt - Founder, Chair
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
07:00am, Tuesday, 16'th Sep 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairpe
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commer
United Therapeutics Corporation (UTHR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
05:31pm, Monday, 08'th Sep 2025
United Therapeutics Corporation (NASDAQ:UTHR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants James Edgemond - CFO & Treasurer Harrison Silv
United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win
04:26pm, Thursday, 04'th Sep 2025
United Therapeutics delivered strong phase 3 TETON-2 results for nebulized Tyvaso in IPF, meeting the primary endpoint and unlocking major catalyst potential. Tyvaso's efficacy in improving FVC in IPF
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
02:51pm, Wednesday, 03'rd Sep 2025
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
United Therapeutics: Is UTHR Stock Still A Buy At $400?
10:10am, Wednesday, 03'rd Sep 2025
United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic
United Therapeutics shares jump on positive lung disease study results
12:35pm, Tuesday, 02'nd Sep 2025
United Therapeutics Corporation (NASDAQ:UTHR) shares surged more than 35% following the release of positive late-stage clinical trial results for its lung disease drug Tyvaso. The company said its TET
Why Is United Therapeutics Stock Rallying On Tuesday?
10:59am, Tuesday, 02'nd Sep 2025
United Therapeutics Corporation UTHR released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).
United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest?
10:09am, Tuesday, 02'nd Sep 2025
Shares of United Therapeutics jumped nearly 40% on Tuesday's opening trade after the company reported its inhaled lung therapy Tyvaso met the main goal in a late-stage study for idiopathic pulmonary f
United Therapeutics shares surge on successful late-stage lung disease study
09:17am, Tuesday, 02'nd Sep 2025
Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the
Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?
12:36pm, Friday, 29'th Aug 2025
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
07:00am, Friday, 29'th Aug 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial O
